Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 new non-executive officers under its Employment Inducement Plan on June 16, 2026, following Nasdaq Listing Rule 5635.
- These restricted stock units vest over four years, with 25% vesting on each anniversary, contingent on continuous employment.
9 Articles
9 Articles
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ('Iovance' or the 'Company”), a biotechnology company focused on innovating,...
Mason City Globe Gazette
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 15, 2026, the Compensation Committee of its Board of Directors granted restricted…
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026 16:05 ET | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of […] The post CAMP4 Therapeutics Announces Induceme…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium